Navigation Links
Development of prosthetic hands stagnated for 20 years
Date:6/12/2012

The development of body-powered prosthetic hands has stagnated for over twenty years. That is the main conclusion of a study by researchers from TU Delft and the University of Groningen into this type of prosthesis, which is published in the American Journal of Rehabilitation Research and Development.

High operating force

The study, which was carried out by researchers from TU Delft and the University of Groningen, measured the force required to operate a number of contemporary body-powered prosthetic hands. The researchers compared the results to earlier measurements from 1987 and came up with remarkable results: today's prosthetic hands perform equally or less well than those from 1987. The grip strength of the hands is insufficient and a very high operating force is required. Another remarkable result: a prosthetic hand developed in 1945 performed better in the test than the newer prosthetic hands.

User overload

TU Delft researcher Gerwin Smit: "The study offers a possible explanation why over half of all people with a body-powered prosthetic hand do not use it or even wear it. Besides this, some prosthetic arm users tend to suffer overload problems over time. These problems may well be a result of the excessive operating force required." This is currently being researched further in Groningen and Delft.

Electrical alternative?

Worldwide over 30% of prosthesis users wear a body-powered prosthesis. A body-powered prosthesis is operated by pulling a cable (a little like the brake cable on your bike). This cable is attached to a harness worn on the opposite shoulder. Subtle movements between the arm wearing the prosthesis and the opposite shoulder pull the cable taut and open the prosthesis. Another popular prosthesis is the electric prosthesis. This is worn by about 40% of prosthesis users worldwide. Then there are also cosmetic prostheses.

The big question that the researc
'/>"/>

Contact: Ilona van den Brink
i.vandenbrink@tudelft.nl
31-152-784-259
Delft University of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge
2. Navigating the Patent Minefield of Embryonic Stem Cell Product Development; Free Kindle Fire Tablet and Research Database with Purchase
3. Mice with big brains provide insight into brain regeneration and developmental disorders
4. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
5. UC Riverside receives grant for global health and development research
6. Navigating the IP Minefield of Human Embryonic Stem Cell Development
7. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
8. New genes contributing to autism and related neurodevelopmental disorders uncovered
9. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
10. Europe meets to discuss progress in energy research and development
11. Promising developments in early diagnosis and treatment of mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... able to change their spots, but corals can change their ... chemical composition of the seawater around them. , That's the ... writing in the July issue of the journal Geology. ... is the first known case of an animal altering the ...
... born infected with human cytomegalovirus, or CMV, and about ... the virus ?almost one an hour. These disabilities can ... of coordination, and seizures. According to the Centers for ... cause of serious disability as Down syndrome, fetal alcohol ...
... Biologists from Washington University in St. Louis and their ... trees of rice varieties and have determined that the ... Asian locales. , Jason Londo, Washington University in Arts ... A. Schaal, Ph.D., Washington University Spencer T. Olin Professor ...
Cached Biology News:Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Innovative method for creating a human cytomegalovirus vaccine outlined 2Biologists find regions of rice domestication 2
(Date:7/10/2014)... in the fight against terrorism with the creation of ... with the use of light and special glass fibres. ... B: Chemical , the researchers describe a novel optical ... low as 6.3 ppm (parts per million). It requires ... "Traditionally explosives detection has involved looking for metals that ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... spiders can sit upside down forever. Nanophysics makes sure of ... an article just published in Physical Review E . ... and spiders that seem to be able to sit still ... for many years. We will soon be able to buy ... gecko,s foot. But the fact is, sooner or later the ...
(Date:7/10/2014)... The new alliance will see the two universities and ... working with business and industry and their complementary academic ... will help to shape the scientific priorities of the ... train up to 300 high-calibre PhD students, will provide ... at NPL, the potential of the Laboratory will be ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... , MALVERN, Pa. ... (AMR) and Decision Resources find that the leading driver ... broad-spectrum activity against gram-positive and gram-negative pathogens. Due to ... surveyed European physicians reveal that they look primarily for ...
... ... Top LASIK surgeons and recognized refractive and cataract surgery ... up-to-date on the latest developments in vision correction surgery, cataract surgery, ... Ophthalmology (AAO) annual meeting in San Francisco, California. Dr. Richard Lindstrom, ...
... VIENNA, Austria, November 19 AFFiRiS AG ... an unexpectedly early,stage of development: the vaccine candidate AD02 is ... This decision by the company,immediately follows the completion of two ... based its fast decision on the first interim,analysis of the ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3